BCR-ABL Gene Rearrangement PCR Quantitative Test
Understanding the BCR-ABL Gene Rearrangement Test
The BCR-ABL Gene Rearrangement PCR Quantitative Test represents a cornerstone in modern hematological diagnostics, specifically designed to detect and quantify the presence of the BCR-ABL fusion gene. This genetic abnormality results from a reciprocal translocation between chromosomes 9 and 22, creating the Philadelphia chromosome – a defining characteristic of chronic myeloid leukemia (CML) and some cases of acute lymphoblastic leukemia (ALL).
This sophisticated molecular test employs real-time polymerase chain reaction (PCR) technology to provide precise quantification of BCR-ABL transcript levels, offering clinicians invaluable insights into disease burden and treatment response. The quantitative nature of this test makes it superior to qualitative alternatives, as it enables monitoring of minimal residual disease and early detection of treatment resistance.
What Does the Test Measure?
The BCR-ABL Gene Rearrangement PCR Quantitative Test specifically detects and measures:
- The presence of BCR-ABL fusion transcripts in blood or bone marrow samples
- The quantitative level of BCR-ABL mRNA expression
- Molecular response to tyrosine kinase inhibitor therapy
- Early signs of treatment resistance or disease progression
- Minimal residual disease levels during treatment monitoring
Who Should Consider This Test?
Clinical Indications and Symptoms
This test is recommended for individuals experiencing symptoms suggestive of chronic myeloid leukemia or those with confirmed diagnoses requiring ongoing monitoring. Key indications include:
- Patients presenting with unexplained fatigue, night sweats, or weight loss
- Individuals with abnormal blood counts showing elevated white blood cells
- Splenomegaly (enlarged spleen) without clear cause
- Newly diagnosed CML patients for baseline assessment
- Patients undergoing tyrosine kinase inhibitor therapy for CML
- Individuals requiring monitoring of treatment response and disease progression
- Suspected cases of Philadelphia chromosome-positive acute lymphoblastic leukemia
Benefits of BCR-ABL Quantitative Testing
Choosing the BCR-ABL Gene Rearrangement PCR Quantitative Test provides numerous clinical advantages:
- Early Detection Capability: Identifies minimal residual disease that may not be detectable through conventional methods
- Treatment Guidance: Helps oncologists and hematologists make informed decisions about therapy adjustments
- Prognostic Value: Provides critical information about disease progression and treatment response
- Rapid Results: Same-day reporting when samples are collected by 9 AM
- High Sensitivity: Detects very low levels of BCR-ABL transcripts for comprehensive monitoring
- Standardized Monitoring: Enables consistent tracking of molecular response according to international guidelines
Understanding Your Test Results
Interpreting BCR-ABL Quantitative Results
Your test results will provide a quantitative measurement of BCR-ABL transcript levels, typically expressed as a percentage relative to a control gene. Key interpretation points include:
- Major Molecular Response (MMR): BCR-ABL levels ≤0.1% indicate excellent treatment response
- Complete Molecular Response: Undetectable BCR-ABL transcripts suggest optimal treatment effectiveness
- Rising BCR-ABL Levels: May indicate developing treatment resistance or disease progression
- Baseline Measurements: Initial testing establishes reference levels for future comparison
It’s crucial to discuss your results with your hematologist or oncologist, who will interpret them in the context of your specific clinical situation and treatment history.
Test Pricing and Availability
| Price Type | Amount (USD) |
|---|---|
| Discount Price | $188 |
| Regular Price | $276 |
Sample Requirements and Processing
Sample Type: 5 mL (3 mL minimum) whole blood or bone marrow in 1 Lavender Top (EDTA) tube
Shipping Instructions: Ship refrigerated. DO NOT FREEZE
Turnaround Time: Sample daily by 9 AM; Report same day
Preparation: No special preparation required
Nationwide Testing Availability
We have branches across all major cities in the United States, ensuring convenient access to this essential diagnostic service. Our network includes locations in:
- New York City and surrounding areas
- Los Angeles and Southern California
- Chicago and the Midwest region
- Houston and Texas metropolitan areas
- Miami and Florida locations
- Philadelphia and Northeast centers
- And many other major metropolitan areas
Take Control of Your Health Today
Early and accurate monitoring of BCR-ABL levels is crucial for effective leukemia management. Our state-of-the-art molecular diagnostics laboratory ensures precise, reliable results that your healthcare team can trust for making critical treatment decisions.
Ready to schedule your BCR-ABL Gene Rearrangement PCR Quantitative Test?
Call or WhatsApp us today at +1(267) 388-9828 to book your appointment or speak with our genetic counseling specialists. Our team is available to answer your questions and help you understand the testing process.
Don’t wait – take the first step toward comprehensive leukemia monitoring and personalized treatment management. Contact us now to schedule your test at our convenient location nearest you.
